Research programme: smart growth factor based therapies - Silver Creek

Drug Profile

Research programme: smart growth factor based therapies - Silver Creek

Latest Information Update: 28 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Silver Creek Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Heart failure; Kidney disorders; Tissue degeneration

Most Recent Events

  • 05 May 2015 Silver Creek Pharmaceuticals receives SBIR grant from the National Institutes of Health for smart growth factors for development in Kidney disorders, Tissue degeneration and Heart failure
  • 05 May 2015 Preclinical trials in Heart failure in USA (unspecified route)
  • 05 May 2015 Preclinical trials in Kidney disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top